Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.970 +0.060 (+0.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
Results published in the Journal of Clinical Psychopharmacology 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
ANGLE Announces Collaboration with Myriad Genetics
Via ACCESS Newswire
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces New $200 Million Credit Facility
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Earns 2025 Great Place To Work Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via... 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators 
From Myriad Genetics, Inc.
Via GlobeNewswire
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Correction: Time of BofA Conference 
From Myriad Genetics, Inc.
Via GlobeNewswire
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance
From Myriad Genetics, Inc.
Via GlobeNewswire
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
More than half say genetic testing for mental health medications could reduce concerns 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025
Management will participate in two upcoming investor healthcare conferences 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting
Podium presentation showcases the clinical application of Precise™ MRD 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing
Study published in the Journal of Clinical Psychopharmacology 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Inducement Awards
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Senior Leadership Transition
Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Included in Forbes America’s Best Employers 2025 List
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.